

April 13, 2022

GE Healthcare Finland Oy Joel Kent Senior Regulatory Affairs Manager Kuortaneenkatu 2 Helsinki, FI-00510 Finland

Re: K213336

Trade/Device Name: Carescape B850, E-musb

Regulation Number: 21 CFR 870.1025

Regulation Name: Arrhythmia Detector And Alarm (Including ST-Segment Measurement And Alarm)

Regulatory Class: Class II

Product Code: MHX, BZK, BZL, BZQ, CAP, CBQ, CBR, CBS, CCK, CCL, DPS, DQA, DQK, DRT,

DSI, DSJ, DSK, DXG, DXN, FLL, GWJ, GWQ, KOI, KRB, MLD, MUD, DPZ, NHO,

NHP, NHQ, OLT, QEM, OLW, OMC, ORT

Dated: March 11, 2022 Received: March 14, 2022

### Dear Joel Kent:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

K213336 - Joel Kent Page 2

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (<a href="DICE@fda.hhs.gov">DICE@fda.hhs.gov</a>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

for

Jennifer Shih Kozen
Assistant Director
Division of Cardiac Electrophysiology,
Diagnostics and Monitoring Devices
Office of Cardiovascular Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

**Enclosure** 

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023

See PRA Statement below.

510(k) Number (if known)
K213336

Device Name
CARESCAPE B850

Indications for Use (Describe)

The CARESCAPE B850 is a multi-parameter patient monitor intended for use in multiple areas within a professional healthcare facility.

The CARESCAPE B850 is intended for use on adult, pediatric, and neonatal patients and on one patient at a time. The CARESCAPE B850 is indicated for monitoring of:

- hemodynamic (including ECG, ST segment, arrhythmia detection, ECG diagnostic analysis and measurement, invasive pressure, non-invasive blood pressure, pulse oximetry, regional oxygen saturation, total hemoglobin concentration, cardiac output (thermodilution and pulse contour), temperature, mixed venous oxygen saturation, and central venous oxygen saturation),
- respiratory (impedance respiration, airway gases (CO2, O2, N2O, and anesthetic agents), spirometry, gas exchange), and
- neurophysiological status (including electroencephalography, Entropy, Bispectral Index (BIS), and neuromuscular transmission).

The CARESCAPE B850 can be a stand-alone monitor or interfaced to other devices. It can also be connected to other monitors for remote viewing and to data management software devices via a network.

The CARESCAPE B850 is able to detect and generate alarms for ECG arrhythmias: atrial fibrillation, accelerated ventricular rhythm, asystole, bigeminy, bradycardia, ventricular couplet, irregular, missing beat, multifocal premature ventricular contractions (PVCs), pause, R on T, supra ventricular tachycardia, tachycardia, trigeminy, ventricular bradycardia, ventricular fibrillation/ventricular tachycardia, ventricular tachycardia, and VT>2. The CARESCAPE B850 also shows alarms from other ECG sources.

The CARESCAPE B850 also provides other alarms, trends, snapshots and events, and calculations, and can be connected to displays, printers and recording devices.

The CARESCAPE B850 is intended for use under the direct supervision of a licensed healthcare practitioner, or by personnel trained in proper use of the equipment in a professional healthcare facility.

CONTINUE ON A SEPARATE PAGE IF NEEDED.					
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)				
Type of Use (Select one or both, as applicable)					
The CARESCAPE B850 is not intended for use in a controlled MR environment.					
Contraindications for using the monitor					

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

GE Healthcare Finland Oy Kuortaneenkatu 2 00510 Helsinki Finland T: +358 10 39411

# 510(k) Summary

In accordance with 21 CFR 807.92 the following summary of information is provided:

# Owner/Contact/Date (807.92(a)(1)):

Date: October 5, 2021

Owner/Submitter: GE Healthcare Finland Oy.

Kuortaneenkatu 2 00510 Helsinki FINLAND

Phone: +358 10 39411

Primary Contact Person: Joel Kent

Senior Regulatory Affairs Manager

GE Healthcare

Phone: 617-851-0943

E-mail: joel.kent@ge.com

Secondary Contact Person: Karin Mårtenson

Regulatory Affairs Leader GE Healthcare Finland Oy

Kuortaneenkatu 2 00510 Helsinki

Finland

Phone: + 358 50 384 6646

E-mail: karin.martenson@ge.com

# Device names (807.92(a)(2)):

<u>Trade Name:</u> CARESCAPE B850

Common/Usual Name: Multiparameter patient monitor (monitor, physiological, patient

(with arrhythmia detection or alarms)

K213336 Page 1 of 7

- <u>Classification Names:</u> 21 CFR 870.1025 Arrhythmia detector and alarm (including STsegment measurement and alarm)
  - 21 CFR 868.1850 spirometer, monitoring (w/wo alarm)
  - 21 CFR 868.1730 computer, oxygen-uptake
  - 21 CFR 868.2375 monitor, breathing frequency
  - 21 CFR 868.2600 monitor, airway pressure (includes gauge and/or alarm)
  - 21 CFR 868.1500 analyzer, gas, enflurane, gaseous-phase (anesthetic conc.)
  - 21 CFR 868.1500 analyzer, gas, desflurane, gaseous-phase (anesthetic conc.)
  - 21 CFR 868.1500 analyzer, gas, sevoflurane, gaseous-phase (anesthetic conc.)
  - 21 CFR 868.1500 analyzer, gas, isoflurane, gaseous-phase (anesthetic conc.)
  - 21 CFR 868.1700 analyzer, gas, nitrous-oxide, gaseous phase (anesthetic conc.)
  - 21 CFR 868.1620 analyzer, gas, halothane, gaseous-phase (anesthetic conc.)
  - 21 CFR 868.1400 analyzer, gas, carbon-dioxide, gaseous-phase
  - 21 CFR 868.1720 analyzer, gas, oxygen, gaseous-phase
  - 21 CFR 870.2340 electrocardiograph
  - 21 CFR 870.2710 oximeter, ear
  - 21 CFR 870.2700 oximeter
  - 21 CFR 870.1425 computer, diagnostic, programmable
  - 21 CFR 870.2300 monitor, cardiac (incl. cardiotachometer & rate alarm)
  - 21 CFR 870.1025 detector and alarm, arrhythmia
  - 21 CFR 870.1100 alarm, blood-pressure
  - 21 CFR 870.1110 computer, blood-pressure
  - 21 CFR 870.1435 computer, diagnostic, pre-programmed, single-function
  - 21 CFR 870.1130 system, measurement, blood-pressure, non-
  - 21 CFR 870.2910 thermometer, electronic, clinical
  - 21 CFR 882.1900 stimulator, auditory, evoked response
  - 21 CFR 882.1400 full-montage standard electroencephalograph
  - 21 CFR 870.2700 Oximeter, Tissue Saturation
  - 21 CFR 868.2775 stimulator, nerve, peripheral, electric
  - 21 CFR 870.1915 probe, thermodilution
  - 21 CFR 870.1025 monitor, st segment with alarm
  - 21 CFR 882.1400 non-normalizing quantitative
  - electroencephalograph software
  - 21 CFR 882.1400 index-generating electroencephalograph software
  - 21 CFR 882.1400 reduced- montage standard electroencephalograph
  - 21 CFR 882.1400 burst suppression detection software for electroencephalograph
  - 21 CFR 870.2700 Cerebral Oximeter

K213336 Page 2 of 7 Product Code: MHX

Subsequent Product Codes: BZK, BZL, BZQ, CAP, CBQ, CBR, CBS, CCK, CCL, DPS,

DPZ, DQA, DQK, DRT, DSI, DSJ, DSK, DXG, DXN, FLL, GWJ, GWQ, KOI, KRB, MLD, MUD, NHO, NHP, NHQ, OLT,

OLW, OMC, ORT, QEM

(807.92(a)(3)):

<u>Predicate Device(s)</u> The primary predicate for this submission is K191323 **CARESCAPE B850** 

Additional predicates / reference devices:

K182868, INVOS PM7100 Patient Monitor, INVOS Adult rSO2

Sensor

K110028, MASIMO RADICAL Y PULSE CO-OXIMETER

**Device Description** (807.92(a)(4)):

CARESCAPE B850 is a new version of a modular multiparameter patient monitoring system. The monitor includes a separate 19-inch touchscreen display, the central processing unit (also called CPU), the CARESCAPE Software, and a module frame F5 or F7. CARESCAPE B850 is equipped with the ePort interface that supports use of PDM or CARESCAPE ONE patient data acquisition modules for patient monitoring. In addition, the F5 module frame has five module slots, and the F7 module frame has seven module slots where patient data acquisition modules (E-Module type), can be connected to perform patient monitoring. The CARESCAPE B850 includes features and subsystems that are optional or configurable.

Intended Use: (807.92(a)(5)):

# **Indications (from labeling)**

The CARESCAPE B850 is a multi-parameter patient monitor intended for use in multiple areas within a professional healthcare facility.

The CARESCAPE B850 is intended for use on adult, pediatric, and neonatal patients and on one patient at a time.

The CARESCAPE B850 is indicated for monitoring of:

• hemodynamic (including ECG, ST segment, arrhythmia detection, ECG diagnostic analysis and measurement, invasive pressure, non-invasive blood pressure, pulse oximetry, regional oxygen saturation, total hemoglobin concentration, cardiac output (thermodilution and pulse contour), temperature, mixed venous oxygen saturation, and central venous oxygen saturation),

K213336 Page 3 of 7

- respiratory (impedance respiration, airway gases (CO2, O2, N2O, and anesthetic agents), spirometry, gas exchange), and
- neurophysiological status (including electroencephalography, Entropy, Bispectral Index (BIS), and neuromuscular transmission).

The CARESCAPE B850 can be a stand-alone monitor or interfaced to other devices. It can also be connected to other monitors for remote viewing and to data management software devices via a network.

The CARESCAPE B850 is able to detect and generate alarms for ECG arrhythmias: atrial fibrillation, accelerated ventricular rhythm, asystole, bigeminy, bradycardia, ventricular couplet, irregular, missing beat, multifocal premature ventricular contractions (PVCs), pause, R on T, supra ventricular tachycardia, tachycardia, trigeminy, ventricular bradycardia, ventricular fibrillation/ventricular tachycardia, ventricular tachycardia, and VT>2. The CARESCAPE B850 also shows alarms from other ECG sources.

The CARESCAPE B850 also provides other alarms, trends, snapshots and events, and calculations, and can be connected to displays, printers and recording devices.

The CARESCAPE B850 is intended for use under the direct supervision of a licensed healthcare practitioner, or by personnel trained in proper use of the equipment in a professional healthcare facility.

# Contraindications for using the monitor

The CARESCAPE B850 is not intended for use in a controlled MR environment.

# <u>Technology</u> (807.92(a)(6)):

The CARESCAPE B850 incorporates incorporates updated software and minor modifications to the hardware.

The fundamental function and operation of the proposed CARESCAPE B850 monitor are unchanged compared to CARESCAPE B850 (K191323).

A summary of the main changes compared to the predicate are listed below in the comparison table.

K213336 Page 4 of 7

Subject Device and Predicate Device Comparison

Specification	CARESCAPE B850	Proposed Proposed	Differences
	(K191323)	CARESCAPE B850	
Patient type	Adult, pediatric & neonatal	Adult, pediatric & neonatal	Identical
	Within a professional healthcare facility (Not intended for MRI)	Within a professional healthcare facility (Not intended for MRI)	Identical
D) & Weight	91 mm x 401 mm x 340 mm (3.6 in x 15.8 in x 13.4 in) and weight 7.5 kg (16.5 lbs)	91 mm x 401 mm x 340 mm (3.6 in x 15.8 in x 13.4 in) and weight 7.5 kg (16.5 lbs)	Identical
	Up to 12 optional E-module slots with F5 and F7 Frames. One slide mount for acquisition module	Up to 12 optional E-module slots with F5 and F7 Frames. One slide mount for acquisition module	Identical
	19" Active matrix color TFT LCD	19" Active matrix color TFT LCD	Identical
parameter windows	Standard view: Up to 8 individual waveforms and up to 20, if horizontal parameter area turned on.	individual waveforms and up to 20, if horizontal	Identical
	E-BIS, E-COP, E-COPSv, E-PiCCO, E-EEGX, E-Entropy, E-Masimo, E-miniC, E-NMT, E-NSATX, E-PP, E-PT, E-sCAiOV, E-sCAiOV, E-sCOV, E-SCOV, E-SCOVX, PDM, CARESCAPE ONE	E-BIS, E-COP, E-COPSv, E-PiCCO, E-EEGX, E-Entropy, E-Masimo, E-miniC, E-NMT, E-NSATX, E-PP, E-PT, E-sCAiO , E-sCAiOV, E-sCO, E-sCOV, E-sCOVX, PDM, CARESCAPE ONE	Identical
components	-Remote Control -CARESCAPE D19KT VER01 display -CARESCAPE RAD, Remote Alarm Device -Keyboard -Mouse -Barcode scanner -Laser Printer	-CARESCAPE D19KT VER01 display -CARESCAPE RAD, Remote Alarm Device -Keyboard -Mouse -Barcode scanner	Equivalent  Added E-musb Interface module that provides a communication path for the OEM owned devices CARESCAPE rSO2 – INVOS and CARESCAPE CO2 – Microstream to the CARESCAPE Bx50 host monitors

K213336 Page 5 of 7

Available	FCG_ST segment	FCG_ST segment	Fauivalent
			Equivalent
measurement parameters	arrhythmia detection, ECG diagnostic analysis and measurement, invasive pressure, non-invasive blood pressure, pulse oximetry, cardiac output (thermodilution and pulse contour), temperature, mixed venous oxygen saturation, and central venous oxygen saturation, impedance respiration, airway gases (CO2, O2, N2O, and anesthetic agents), spirometry, gas exchange,	arrhythmia detection, ECG diagnostic analysis and measurement, invasive pressure, non-invasive blood pressure, pulse oximetry, regional oxygen saturation, total hemoglobin concentration, cardiac output (thermodilution and pulse contour), temperature, mixed venous oxygen saturation, and central venous oxygen saturation, impedance respiration, airway gases (CO2, O2,	Equivalent  Added hemodynamic parameters (in bold) that are previously cleared but are new to the monitor: regional oxygen saturation and total hemoglobin concentration, often referred to as rSO2 and SpHb. The Indications for Use were updated accordingly.  The CARESCAPE B850 does not change the measurement or algorithm of these parameters but simply displays the values from the OEM owned
			CARESCAPE parameter devices
	Entropy, Bispectral Index	agents), spirometry, gas	CARESCAPE SpO2 –Masimo and
		exchange,	CARESCAPE rSO2 –INVOS.
		electroencephalography, Entropy, Bispectral Index (BIS), neuromuscular transmission.	6. M. B. 6. 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
EK-Pro arrhythmia detection algorithm	EK-Pro V14	EK-Pro V14	Identical
Printing		Local recorder/printer and	Identical
	Printings for waveforms, alarms waveforms,	networked laser printer. Printings for waveforms, alarms waveforms, numeric trends.	
Mounting	Multiple GCX mounting	Multiple GCX mounting	Identical
options	systems	systems	
	alarms Adjustment of alarm settings Possibility to set critical alarm limits Alarm On/Off functionality and	Alarm management core functionalities: Classification and notification of alarms Adjustment of alarm settings Possibility to set critical alarm limits Alarm On/Off functionality and audio silencing	Identical
Networking capability	CARESCAPE Network LAN/VLAN	CARESCAPE Network LAN/VLAN	Identical
Network interface	10baseT, 100baseT	10baseT, 100baseT	Identical

<u>Determination of</u> <u>Substantial Equivalence</u> (807.92(b)(1):

Summary of Non-Clinical Tests:

K213336 Page 6 of 7

Bench testing related to software, hardware and performance including applicable consensus standards was conducted on the CARESCAPE B850, demonstrating the design meets the specifications.

The hardware bench testing included electromagnetic compatibility, electrical safety, environmental, and usability. Software testing included software design, development, verification, validation and traceability.

# Clinical (807.92(b)(2)): Summary of Clinical Tests:

The subject of this premarket submission, CARESCAPE B850 did not require clinical studies to support substantial equivalence.

Conclusion (807.92(b)(3)): GE Healthcare considers the CARESCAPE B850 to be as safe, as effective, and the performance to be substantially equivalent to the predicate device.

K213336 Page 7 of 7